Leveraging Bi-& Tri-Specific Antibodies for a Deep & Targeted Immune Reset

• Understanding the mechanism of action for bi- and tri-specific antibodies enhancing cytotoxicity and phagocytosis through forced proximity for B-cell depletion
• Exploring how multi-specificity can overcome therapeutic resistance by targeting multiple antigens across the B-cell lineage
• Managing CRS risk for CD3 engagement in non-oncology populations in non-IgG-like multi-specific antibody constructs

Speakers:

Tap Maniar

CMO

Oblenio Bio